» Articles » PMID: 31381135

The Functional Interlink Between AR and MMP9/VEGF Signaling Axis is Mediated Through PIP5K1α/pAKT in Prostate Cancer

Overview
Journal Int J Cancer
Specialty Oncology
Date 2019 Aug 6
PMID 31381135
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Currently, no effective targeted therapeutics exists for treatment of metastatic prostate cancer (PCa). Given that matrix metalloproteinases 9 (MMP9) and its associated vascular endothelial growth factor (VEGF) are critical for tumor vascularization and invasion under castration-resistant condition, it is therefore of great importance to define the functional association and interplay between androgen receptor (AR) and MMP9 and their associated key survival and invasion pathways in PCa cells. Here, we found that there was a significant correlation between MMP9 and AR protein expression in primary and metastatic PCa tissues, and a trend that high level of MMP9 expression was associated with poor prognosis. We demonstrated that constitutive activation of AR increased expression of MMP9 and VEGF/VEGF receptors. We further showed that AR exerts its effect on MMP9/VEGF signaling axis through PIP5K1α/AKT. We showed that MMP9 physically interacted with PIP5K1α via formation of protein-protein complexes. Furthermore, elevated expression of MMP9 enhanced ability of AR to activate its target gene cyclin A1. The elevated sequential activation of AR/PIP5K1α/AKT/MMP9/VEGF signaling axis contributed to increased invasiveness and growth of metastatic tumors. Conversely, treatment with PIP5K1α inhibitor significantly suppressed invasiveness of PCa cells expressing constitutively activated AR, this was coincident with its inhibitory effect of this inhibitor on AR/MMP9/VEGF pathways. Our results suggest that AR and MMP9-associated network proteins may be effectively targeted by blocking PIP5K1α/AKT pathways using PIP5K1α inhibitor in metastatic PCa.

Citing Articles

Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota.

Chen L, Xu Y, Wang Y, Ren Y, Dong X, Wu P Mol Cancer. 2024; 23(1):229.

PMID: 39395984 PMC: 11470719. DOI: 10.1186/s12943-024-02137-1.


Silencing of matrix metalloprotease-12 delays the progression of castration-resistant prostate cancer by regulating autophagy and lipolysis.

Zheng X, Xie X, Wang W, Wang L, Tan B Braz J Med Biol Res. 2024; 57:e13351.

PMID: 38511770 PMC: 10946229. DOI: 10.1590/1414-431X2024e13351.


The Potential of Extracellular Matrix- and Integrin Adhesion Complex-Related Molecules for Prostate Cancer Biomarker Discovery.

Samarzija I Biomedicines. 2024; 12(1).

PMID: 38255186 PMC: 10813710. DOI: 10.3390/biomedicines12010079.


The Potential of Glycyrrhiza from "Medicine Food Homology" in the Fight against Digestive System Tumors.

Lu D, Yang Y, Du Y, Zhang L, Yang Y, Tibenda J Molecules. 2023; 28(23).

PMID: 38067451 PMC: 10708138. DOI: 10.3390/molecules28237719.


Lactoferrin and Activated Protein C: Potential Role in Prevention of Cancer Progression and Recurrence.

Akhtar N, Wani A, Jan M, Sinha S, Devkota H, Li Z Int J Mol Cell Med. 2023; 12(1):86-99.

PMID: 37942258 PMC: 10629726. DOI: 10.22088/IJMCM.BUMS.12.1.86.


References
1.
Aalinkeel R, Nair B, Reynolds J, Sykes D, Mahajan S, Chadha K . Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest. 2011; 40(5):447-64. DOI: 10.3109/08820139.2011.557795. View

2.
Sarwar M, Syed Khaja A, Aleskandarany M, Karlsson R, Althobiti M, Odum N . The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor. Oncogene. 2018; 38(3):375-389. PMC: 6336681. DOI: 10.1038/s41388-018-0438-2. View

3.
Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67. PMC: 2862057. DOI: 10.1016/j.cell.2010.03.015. View

4.
van den Bout I, Divecha N . PIP5K-driven PtdIns(4,5)P2 synthesis: regulation and cellular functions. J Cell Sci. 2009; 122(Pt 21):3837-50. DOI: 10.1242/jcs.056127. View

5.
Chen C, Welsbie D, Tran C, Baek S, Chen R, Vessella R . Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004; 10(1):33-9. DOI: 10.1038/nm972. View